363P - High adipocytokines and IL-18bp serum levels are associated with lower objective response rate after neoadjuvant treatment in breast cancer patients with metabolic syndrome

Background

Metabolic syndrome (MetS) has been identified as a factor related to a worse prognosis in breast cancer. However, the association between adipocytokines and IL-18bp serum levels, MetS, and breast cancer is not demonstrated.

Methods

We prospectively evaluated 151 women with breast cancer eligible for neoadjuvant chemotherapy (NAC). We studied adipocytokines (resistin and leptin) and IL-18bp serum levels and their association with MetS, patients’ clinical and laboratory data, and clinical and pathological responses after NAC. Data analysis used the Fisher/Chi-Square and Mann-Whitney Tests (SPSS v20.0, p<0.05). Study approval number 5.332.237.

Results

134 subjects (95.7%) achieved clinical objective response (complete + partial). Among the 151 patients evaluated, 82 (54.3%) had MetS, with HDL-C <50 mg/dl being the most frequent criterion (n=72, 87,8%). Age>45 years, postmenopausal status, obesity, NAC dose reduction, and delay in performing surgery were more associated with the MetS group (p<0.01). MetS breast cancer patients with high resistin levels presented with positive lymph nodes (97%), >=88 cm waist circumference (94%), and invasive breast carcinoma of no special type (100%) versus the group with low levels of resistin (p<0.05). Additionally, high IL-18bp levels were associated with non-luminal A breast cancers (94%) versus 73% of patients with IL-18bp low levels (p<0.05). Leptin was elevated in patients with hyperglycemia and hypertriglyceridemia, while IL18-bp levels increased in subjects with HDL-C < 50md/dl (p<0.05). The higher frequency of objective response was associated with no need for dose reduction and low serum IL-18bp concentration (p<0.05).

Conclusions

High adipocytokines and IL-18bp serum levels are associated with lower objective response rates after neoadjuvant treatment in breast cancer patients with metabolic syndrome.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

L. Mont'Alverne Arruda.

Funding

Funcap, CNPq, Ebserth, Capes.

Disclosure

All authors have declared no conflicts of interest.